Tyrosine kinase inhibitors (TKIs) targeting EGFR mutations have been developed for the treatment of patients with advanced lung adenocarcinoma harboring EGFR mutations, such as in exon 19 (in-frame deletions) and L858R (leucine-to-arginine substitution at codon858 point mutation in exon 21) [3,4,5]. This evidence concerns the gene EGFR and lung adenocarcinoma.